voucher cash, when is it coming? See latest NR
the Rare Pediatric Disease Priority Review Voucher ("PRV") by its subsidiary, Prometic Biotherapeutics Inc. ("PBT"), which would be payable to Liminal prior to closing the divestment of its remaining plasma-derived therapeutics business operated through PBT (the "Second Closing").
-----------------------------------------------------------------------------------------------------------------
everybody on this board and the market manipulators want your shares... this stock wil ride high next days...
With this FDA ok, we can sell that riplazym voucher...market price is between 80M$-120M$ u.s., so lets say 100M$ u.s., we get 70%.... 70M$ u.s. + 17M$ u.s. we cashed already, around 100M$ can$ , lmnl will be able to execute big time and do more deals like this (sell or partner), we gat some in the oven already. Doyour dd. Dont listen to the clown$ operating on this board. They are here for $$$... accumulation time....